Lecture Notes

**Lecture Coverage:**
- Heart Arrhythmias
- Class I: Na<sup>+</sup> Channel Blockers
- Class II: β Blockers
- Class III: K<sup>+</sup> Channel Blockers
- Class IV: Ca<sup>2+</sup> Channel Blockers
- Other Antiarrhythmic Drugs

---
#### **Heart Arrhythmias**
- Deviation from the normal sinus rhythm of SA node
	- Tachycardia & Bradycardia


**Action Potential of Cardiac Muscles**
- Caused by change in membrane conductance to ions ([[Pasted image 20250322114547.png|Diagram]])
- Can be calibrated by drugs to treat Arrhythmias
	- Drug Class classified by AP Phase Affected ([[Pasted image 20250322184631.png|Diagram]])

| Phase |       <        | Ion Conductance                                                       | Corresponding Drug Class                 |
| :---: | :------------: | --------------------------------------------------------------------- | ---------------------------------------- |
|   4   |    Resting     | K<sup>+</sup> Stabilization at -90mV (Rectifier Channels)             | II: β Blockers                           |
|   0   | Depolarization | Na<sup>+</sup> Influx                                                 | Iabc: Na<sup>+</sup> Channel Blockers    |
|   1   | Repolarization | K<sup>+</sup> Efflux (Transient Channels)                             |                                          |
|   2   |    Plateau     | K<sup>+</sup> Efflux (Rectifier Channels) V.S. Ca<sup>2+</sup> Influx | IV: Ca<sup>2+</sup> Channel Blockers     |
|   3   | Repolarization | K<sup>+</sup> Efflux (Rectifier Channels)                             | III & Ia: K<sup>+</sup> Channel Blockers |

**Symptoms of Heart Arrhythmias**
- Abnormal <abbr Title="Effective Refractory Period">ERP</abbr>
	- Characterized by Abnormal QT Interval
	- Mainly Affected by Phase 3 of AP
- Abnormal Atrial to Ventricular Conduction Time
	- Characterized by Abnormal PR Interval


#### **Class I: Na⁺ Channel Blockers**
- Slows Na<sup>+</sup> Influx → Slows Cardiac Muscle AP Initiation & Propagation
- Categorized into 3 Subclasses by Effect on AP Duration & ERP

| Class  | Note                                                                                                       | AP Duration & ERP |               Drug Examples               |
| :----: | :--------------------------------------------------------------------------------------------------------- | :---------------: | :---------------------------------------: |
| <br>1A | Moderate Na<sup>+</sup> & K<sup>+</sup> Channel Blockers<br>- Partially Class III Drugs                    |       <br>↑       | Quinidine<br>Disopyramide<br>Procainamide |
| <br>1B | Weak Na<sup>+</sup>  Channel Blockers<br>                                                                  |       <br>↓       |        <br>Mixeletine<br>Lidocaine        |
|   ^    | Use-Dependent Blockers<br>- Drug Effectiveness ∝ HR                                                        |         ^         |                     ^                     |
| <br>1C | Strong Na<sup>+</sup>  Channel Blockers                                                                    |       <br>-       |       <br>Propafenone<br>Flecainide       |
|   ^    | ↓ <abbr Title="Within Ventricular Myocytes">His-Purkinje</abbr> Conduction Velocity<br>- QRS Wave Widening |         ^         |                     ^                     |


#### **Class II: β Blockers**
- ↓ Sympathetic Stimulation → Indirectly ↓ Ion Conductance

| Affected Phases                      | Description                                                                                                   | Effect                                                                                                                                  |
| ------------------------------------ | ------------------------------------------------------------------------------------------------------------- | --------------------------------------------------------------------------------------------------------------------------------------- |
| Phase 0 (Na<sup>+</sup> Influx)      | Indirectly ↓ Na<sup>+</sup> Influx                                                                            | ↓ Conduction Velocity                                                                                                                   |
| <br>Phase 2 (Ca<sup>2+</sup> Influx) | ↓ Adenylyl Cyclase (ATP → cAMP) <br>→ ↓ L-Type Ca<sup>2+</sup> Channel Activity<br>→ ↓ Ca<sup>2+</sup> Influx | <br>↓ Premature Contraction                                                                                                             |
| Phase 4 (RMP)                        | ↓ Na<sup>+</sup> & Ca<sup>2+</sup> Influx<br>→ Stabilize RMP                                                  | ↓ Slope during Phase 4 Depolarization<br>→ ↓ <abbr Title="Self-Initiated Myocardial Contraction">Automaticity</abbr> (Ectopic Activity) |
| Parasympathetic Stimulation          | ↓ Catecholamine Effect on Heart                                                                               | ↓ Heart Rate & Contractility                                                                                                            |


#### **Class III: K⁺ Channel Blockers**
- ↓ K<sup>+</sup> Efflux 
	- → Prolongs AP Duration & ERP
- Drug Examples:
	- Sotalol
	- Amiodarone: Moderate Na<sup>+</sup> Channel Blocker (Partially Class I)
	- Dronedarone: For Symptomatic Non-permanent <abbr Title="Atrial Fibrillation">AF</abbr>
		- ↑ Risk in Severe Heart Failure Patients


#### **Ca²⁺ Channel Blockers**
- Blocks L-Type Ca<sup>2+</sup> Calcium Channels → ↓ Ca<sup>2+</sup> Efflux
	- ↓ SA & AV Depolarization Rate → ↓ HR
	- ↓ Myocardial Contractility
- Drug Examples
	- Verapamil
	- Diltiazem


#### **Other Antiarrhythmic Drugs**
**Drugs for Tachyarrhythmias**
- 